Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN624 (Tanezumab) in post-herpetic neuralgia
NCT00568321Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2007
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tanezumab in postherpetic neuralgia (PHN), sponsored by Pfizer. Started Dec 2007; status: completed.
02
Drugs
tanezumab
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00568321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00568321.